C. BunnagB. DhorranintraP. JareoncharsriMahidol University2018-08-102018-08-101991-01-01Asian Pacific Journal of Allergy and Immunology. Vol.9, No.1 (1991), 45-500125877X2-s2.0-0025785522https://repository.li.mahidol.ac.th/handle/20.500.14594/22059Allerglobuline is a human gammaglobulin preparation which has been reported to have a protective effect against Type 1 allergic diseases and chronic infection of the upper respiratory tract both in adults and children. This study included 64 patients suftering from perennial allergic rhinitis and/or chronic infection of the nose, paranasal sinuses and pharynx. All patients received Allerglobuline 10 ml intramuscular injection once a week for 5 times then once a month for another 3 times. Blood samples were taken before the first and after the last injections to assay for the levels of Igs G, A, M and E. The therapeutic responses were evaluated after the fifth injections by dividing into 5 grades (from Grade I = excellent to Grade V = no response). Statistical analysis revealed that there was no significant difference between the pre- and post-treatment levels of Igs, G, A and M. But the level of IgE decreased significantly after 8 injections (p < 0.001). There was no correlation between the level of immunoglobulins and grade of therapeutic responses. But the number of patients who respond satisfactorily to Allerglobuline treatment increased from 62.26% after 5 injections to 77.36% after 8 injections. This difference does not reach the statistically significant level but is noteworthy.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS